NPM1 mutation-specific CD8+ T cells can directly lyse leukemia cells harboring NPM1 mutations, whereas CD4+ T cells support CD8+ T cell function and induce HLA class II-mediated anti-tumor cytotoxic responses. Here, CD8A is linked to leukemia.